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The purpose of the study is to quantify the level of uptake of administered radionuclide in
primary bone tumors for patients undergoing bone scintigraphy. Retrospective study on 48
patient's scintigrams to quantify the uptake levels of administered radiopharmaceuticals
was performed in a nuclear medicine unit in Ghana. Patients were administered with ac-
tivity ranging between 0.555 and 1.110 MBq (15e30 mCi), and scanned on Siemens e.cam
SPECT system. Analyses on scintigrams were performed with Image J software by drawing
regions of interest (ROIs) over identified hot spots (pathologic sites). Nine skeletal parts
namely cranium, neck, shoulder, sacrum, sternum, vertebra, femur, ribcage, and knee
were considered in the study, which involved 96 identified primary tumors. Radionuclide
uptakes were quantified in terms of the estimated counts of activity per patient for iden-
tified tumor sites. Average normalized counts of activity (nGMC) per patient ranged from
5.2759 ± 0.6590 cts/mm2/MBq in the case of cranium tumors to 72.7569 ± 17.8786 cts/mm2/
MBq in the case of ribcage tumors. The differences in uptake levels could be attributed to
different mechanisms of Tc-99m MDP uptake in different types of bones, which is directly
related to blood flow and degree of osteoblastic activity. The overall normalized count of
activity for the 96 identified tumors was estimated to be 23.0350 ± 19.5424 cts/mm2/MBq.
The study revealed highest uptake of activity in ribcage and least uptake in cranium.
Quantification of radionuclide uptakes in tumors is important and recommended in
assessing patient's response to therapy, doses to critical organs and in diagnosing tumors.
Copyright © 2014, The Egyptian Society of Radiation Sciences and Applications. Production
and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Bone scintigraphy procedure in nuclearmedicine uses Tc-99m
Methylene Diphosphonate (MDP) for diagnostic evaluation of
patients withmetastatic and nonmetastatic conditions of the
bones (Habib, 2006; O'Reilly, Shields, & Testa, 2000). It is a
valuable tool for early diagnosis, localization and quantifica-
tion ofmuscular involvement in bone diseases, and also useful
in monitoring therapeutic responses (Bar-Sever, Mukamel,
Harel, & Hardoff, 2000; Lim, Sohn, & Park, 2000; Otsuka et al.,
1988). Bone scintigraphy is highly sensitive, and its greatest
strength lies in the ability to provide early physiologic infor-
mation about the involved bone and to evaluatemultiple areas
in a single, relatively rapid examination. Diagnostic specificity
and accuracy for many bone scintigraphic examinations have
improved due to improvement in imaging techniques such as
Single Photon Emission Computed Tomography (SPECT) and
three-phase scanning, coupled with quantitative assessments
of scintigrams (Bombardieri et al., 2003; Lurye, Castronovo, &
Potsaid, 1977; McNail, 1978).
Primary bone tumors are tumors with their origin in the
cells of the bone itself, and early diagnosis of this condition is
best achieved with scintigraphy among other imaging mo-
dalities. Bone scintigraphy depends ultimately on the ability
of a nuclearmedicine physician to accurately interpret images
obtained after scanning patients. It is at this stage that the
subjectivity of the physician impacts on the outcome of the
patient's diagnosis. Hence, it is desirous to adopt measures of
decreasing as much as possible the physician's subjectivity in
the interpretation of the scan.
Single Photon Emission Computed Tomography system en-
hances the contrast resolution of bone scans by screening out
overlying or underlying tissues. This results in improved detec-
tion and localization of small abnormalities, especially in the
spine, pelvis, and knees. In some cases, increased activity not
seenoronlyvaguelydetectedonplanarviewscanbedefinitively
demonstrated with SPECT. The images are sometimes re-
projected into a three-dimensional one which is viewed in a
dynamic rotating format on computer monitor, facilitating the
demonstration of pertinent findings to the referring physician.
Many authors (Hasford et al., 2010; Jones, Francis, & Davis,
1978; Ludwig, Kumpan, & Sinzinger, 1982; Mettler &
Guiberteau, 1998; Subramanian, McAfee, Blojr, KaIIfeIz, &Fig. 1 e System of image acquisitioThomas, 1975; Thrall, Geslien, Corcoron, & Johnson, 1975) have
over the years performed studies on radionuclide bone scintig-
raphy in nuclear medicine, qualitatively. However, quantitative
approach has proved to have added advantage due to its ability
to quantify radionuclide uptake levels in various parts of the
body. The application of credible quantitative assessment tools
such as Image J to analyze the uptakes would aid in accurate
interpretation of bone scintigrams by developing mechanisms
that rely not somuch onhowphysicians see a bone scan, but on
quantitative data provided by the software (Collins, 2007).
In addition to being readily available for no cost on the
internet, Image J is supported by a wide range of constantly
evolving user-created functionalities to address a remarkable
range of applications, complementing commercial software
that typically comes with imaging instruments. The software
operates on a range of platforms like Windows, Mac, and
Linux for image processing.
The aim of this study is to quantify and assess radionuclide
uptake levels for primary bone tumors in various parts of the
skeletal system. The uptake levels are characterized by the
counts of activitymeasured from specific regions of interest in
the patient scintigrams.2. Methodology
2.1. Acquisition of bone scintigrams
Patients undergoing bone scans in a nuclear medicine unit in
Ghana were intravenously administered with Tc-99m MDP
soon after preparation of radiopharmaceutical (Tc-99mMDP).
Administered activity typically ranged from 0.555 to 1.110MBq
(15e30mCi) depending on a patient's weight and age. To aid in
rapid clearance of radioisotope from the bladder, patients
were adviced to drink four to six glasses of water between
time of injection and time of image acquisition. Whole-body
bone scintigrams were acquired with a Siemens e.cam
SPECT system which was equipped with a Low Energy All
Purpose (LEAP) collimator. The process of image acquisition is
shown in Fig. 1. Images were acquired with a matrix size of
256  1024 and displayed in grayscale on the system's com-
puter unit for a resident nuclear medicine physician's inter-
pretation and diagnosis.n using e.cam SPECT system.
Fig. 2 eWhole-body bone scintigram of patient showing hot (increased uptake) spots.
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patient's scintigram. Bone scintigrams used for this study
were retrieved from the database of the nuclear medicine
unit, and radionuclide uptake levels in identified primary bone
tumors were analyzed using Image J quantitative tool.2.2. Image J software
Image J software is a comprehensive image quantitative
analytical tool which displays, edits, analyzes, processes,
saves and prints images. The software also supports standard
image processing functions such as contrast manipulation,
sharpening, smoothing, edge detection, median filtering and
thresholding, histogram generation, and profile plots (Burger
& Burge, 2007; Collins, 2007; Dougherty, 2009). The program
was installed on a computer and used in the analyzing the
retrieved scintigrams.2.3. Radionuclide uptake level assessment
Whole-body bone scintigrams with identified primary bone
tumors of 48 patients were retrieved from the database of the
nuclear medicine department for this study. The images were
acquired with the Siemens SPECT system between 2007 and
2012, and diagnosis performed by resident nuclear medicine
physicians. Due to ethical reasons, the involved patients were
coded with ID numbers to hide their identities.
Nine skeletal parts were considered in this study due to the
dominance of primary bone tumors in those sites than the
remaining skeletal parts. The parts are cranium, neck, shoul-
der, sacrum, sternum, vertebra, femur, ribcage, and knee.
The sampled scintigrams were analyzed retrospectively by
successively importing them into Image J software and
drawing regions of interest (ROI) over observable tumor sites
(hot spots). With bone tumors usually having oval or rounded
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ing the ROIs (Bader & Nagel, 1995; Dougherty, 2009; IAEA,
2006), hence best approximation was achieved. From the
selected ROIs in each patient's scintigram, counts of activity
were obtained, and recorded for the analyses. For each tumor
site, counts of activity in the anterior and posterior viewswere
obtained using the software and the geometric mean count
(GMC) estimated using Eq. (1). The GM counts of activity for
the tumor sites were then normalized relative to the respec-
tive area of ROI and injected activity. The normalized counts
(nGMC), which gives quantified figure for the radionuclide
uptake level, was estimated using Eq. (2).
GMC ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Anterior Mean Counts Posterior Mean Counts
p
(1)
nGMCðUptake LevelÞ ¼ GMCðctsÞ
Area of ROIðmm2Þ  Injected ActivityðMBqÞ
(2)
Estimated average normalized counts for the skeletal parts
and its associated Root Mean Square Error (RMSE) or Standard
Deviation (SD) are presented in Table A1e9 (in the appendix).
The RMSE values were estimated using Eq. (3).
SD ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP ðx xÞ2
N
s
(3)
where x is the mean of N sampled values.3. Results and discussion
Over the years, scintigraphy has been very useful for assessing
a number of bone diseases and conditions such as benign and
primary malignant bone tumors, metastatic bone tumors,
traumatic and sports injuries of bone, avascular necrosis, and
osteoarthritis. Quantifying radionuclide uptakes have even
improved the assessments of these conditions and many
others in nuclear medicine.
Detailed results in this study are presented in Table A1e9
(in the appendix), and summarily presented in Fig. 3. The
graph shows the radionuclide uptake level per patient for each
of the nine skeletal parts and their respective estimated
standard errors. A total of 96 tumors from the 48 patients
considered in the studywere analyzed, resulting in an average
of 2 tumors per patient. For the studied population, patientsFig. 3 e Normalized radionuclide uptake level for patients'
skeletal parts.with primary bone tumors in the knee were most dominant
with 34.4%, and patientswith tumors in the sacrumand femur
were least with 2.1% each.
The average nGMC per patient ranged from
5.2759 ± 0.6590 cts/mm2/MBq in the case of cranium tumors to
72.7569 ± 17.8786 cts/mm2/MBq in the case of ribcage tumors.
High count of activity is associated with high radionuclide
uptake level and vice versa. Hence, results of the study gives
an indication that primary tumors in the ribcage have higher
radionuclide uptake levels than the remaining eight skeletal
parts considered in this study, although this may not be
exhaustive due to factors such as stage of the tumors and the
aggressiveness of the bone diseases. The observation could be
attributed to the mechanism of Tc-99mMDP uptake, which is
directly related to blood flow and degree of osteoblastic ac-
tivity in bones (Bader & Nagel, 1995).
The average normalized uptake for the entire tumor sites
in the studied patient population is estimated in Table 1 to be
23.0350 ± 19.5424 cts/mm2/MBq. Thus average uptakes in the
neck (31.9093 cts/mm2/MBq), vertebra (29.6918 cts/mm2/MBq)
and ribcage (72.7569 cts/mm2/MBq) are seen to be higher than
the overall average, while uptakes in the remaining sites are
lower. The high uptake in these sites could be due to factors
such as stage of the tumors and the aggressiveness of the bone
diseases among others.
Although planar bone scintigraphy is less specific than
radiography in the diagnosis of primary bone tumors, the use
of pinhole scintigraphy in recent times, however, is changing
that perception. With magnification, bone scintigraphy has
been shown to be capable of making an accurate diagnosis of
many tumors and tumorous conditions of the bone such as
bone cysts, giant cell tumors, osteochondroma, osteoid oste-
oma, Paget's bone disease, fibrous dysplasia and primary
malignant bone tumors such as osteosarcoma (IAEA, 2006).
Quantification has even improved further the assessment of
bone tumors by helping in the detection of soft tissue invasion
of osteosarcoma and bone-to-bone metastasis.4. Conclusion
Quantification of radionuclide uptake levels in primary tu-
mors has been performed on scintigraphic images usingTable 1 e Average normalized uptake for the studied
population.
Skeletal part No. of patients nGMC
(cts/mm2/MBq)
Errorðx xÞ2
Cranium 5 5.2759 315.3841
Neck 11 31.9093 78.7540
Shoulder 14 18.8110 17.8418
Sacrum 2 9.4843 183.6203
Sternum 9 10.0070 169.7276
Vertebra 15 29.6918 44.3136
Femur 2 17.5104 30.5207
Ribcage 5 72.7569 2472.2718
Knee 33 11.8680 124.7009
Ave. nGMC
x ¼ 23:0350
St. Deviation
SD ¼ 19:5424
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highest uptake of activity in the ribcage and least uptake in
the cranium, in comparison with seven other skeletal parts
considered in the study. The differences in uptake levels are
attributable to different mechanisms of Tc-MDP uptake
which is directly related to blood flow and degree of osteo-
blastic activity. Quantification of radionuclide uptake in tu-
mors is important and recommended in assessing patient's
response to therapy, doses to critical organs and in diag-
nosing tumors.Source(s) of support
Self financed by authors.Table A1 e Normalized geometric mean count for ROI's in the
Patient ID Administered activity (MBq) Area of ROI (mm
P009 0.803 27.874
P023 0.814 27.581
P031 0.770 27.569
P032 0.951 27.996
P040 0.784 27.874
Table A2 e Normalized geometric mean count for ROI's in the
Patient ID Administered activity (MBq) Area of ROI (mm
P001 0.929 3.710
P004 0.770 3.857
P012 0.910 3.661
P013 0.773 4.027
P014 0.673 3.796
P015 0.777 4.259
P017 0.673 4.003
P018 0.611 3.979
P022 0.524 4.198
P037 0.585 4.052
P038 0.648 4.259
Table A3 e Normalized geometric mean count for ROI's in the
Patient ID Administered activity (MBq) Area of ROI (mm
P007 0.814 12.692
P008 0.895 12.485
P009 0.803 12.692
P011 0.685 12.473
P012 0.910 12.497
P013 0.773 12.814
P014 0.673 12.485
P015 0.777 12.643
P016 0.803 12.485
P017 0.673 12.692
P020 0.640 12.814
P031 0.770 12.814
P040 0.784 12.485
P043 0.681 12.814Conflicting interest
There is no conflict of interest.
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Appendixcranium.
2) GMC (cts) nGMC (cts/mm2/MBq) Error ðx xÞ2
93.100 4.1600 1.2452
131.321 5.8492 0.3288
125.670 5.9231 0.4189
131.223 4.9292 0.1202
120.644 5.5178 0.0586
Ave (x) ¼ 5.2759 SD ¼ 0.6590
neck.
2) GMC (cts) nGMC (cts/mm2/MBq) Error ðx xÞ2
94.481 27.4217 20.1385
125.787 42.3761 109.5532
74.472 22.3489 91.4017
85.657 27.5064 19.3862
63.586 24.8749 49.4827
107.584 32.5102 0.3610
73.685 27.3351 20.9238
89.799 36.9668 25.5779
78.378 35.6358 13.8867
86.296 36.4303 20.4388
103.680 37.5965 32.3440
Ave (x) ¼ 31.9093 SD ¼ 6.0565
shoulder.
2) GMC (cts) nGMC (cts/mm2/MBq) Error ðx xÞ2
198.423 19.2060 0.1561
145.945 13.0552 33.1288
191.573 18.7993 0.0001
170.894 20.0162 1.4527
150.290 13.2126 31.3420
166.252 16.7778 4.1339
165.979 19.7420 0.8669
192.182 19.5633 0.5660
207.563 20.7062 3.5918
163.586 19.1400 0.1083
177.828 21.6804 8.2337
194.116 19.6839 0.7620
193.616 19.7704 0.9205
191.924 22.0001 10.1707
Ave (x) ¼ 18.8110 SD ¼ 2.6109
Table A4 e Normalized geometric mean count for ROI's in the sacrum.
Patient ID Administered activity (MBq) Area of ROI (mm2) GMC (cts) nGMC (cts/mm2/MBq) Error ðx xÞ2
P023 0.814 12.546 62.312 6.1016 11.4428
P024 0.607 12.814 100.048 12.8670 11.4428
Ave (x) ¼ 9.4843 SD ¼ 3.3827
Table A5 e Normalized geometric mean count for ROI's in the sternum.
Patient ID Administered activity (MBq) Area of ROI (mm2) GMC (cts) nGMC (cts/mm2/MBq) Error ðx xÞ2
P004 0.770 12.351 105.727 11.1229 1.2453
P010 0.814 12.216 38.026 3.8241 38.2285
P018 0.611 12.314 81.039 10.7798 0.5972
P019 0.503 12.729 60.958 9.5169 0.2402
P020 0.640 12.692 69.693 8.5785 2.0406
P034 0.585 12.399 90.872 12.5367 6.3996
P036 0.463 12.314 82.595 14.5025 20.2095
P038 0.648 12.692 87.599 10.6593 0.4255
P044 0.418 12.351 44.112 8.5423 2.1454
Ave (x) ¼ 10.0070 SD ¼ 2.8192
Table A6 e Normalized geometric mean count for ROI's in the vertebra.
Patient ID Administered activity (MBq) Area of ROI (mm2) GMC (cts) nGMC (cts/mm2/MBq) Error ðx xÞ2
P001 0.929 4.662 113.996 26.3295 11.3056
P004 0.770 4.760 103.011 28.1198 2.4714
P005 0.951 4.442 127.381 30.1572 0.2166
P006 0.858 4.467 69.472 18.1177 133.9597
P007 0.814 4.345 135.974 38.4452 76.6206
P010 0.814 4.882 86.792 21.8402 61.6476
P011 0.685 4.442 87.598 28.8099 0.7778
P014 0.673 4.442 96.135 32.1388 5.9877
P020 0.640 4.577 104.173 35.5571 34.4014
P022 0.524 4.442 76.546 32.8911 10.2355
P027 0.688 4.930 103.384 30.4714 0.6076
P032 0.951 4.747 137.887 30.5470 0.7314
P035 0.433 4.833 91.168 43.5751 192.7439
P045 1.110 4.760 158.954 30.0844 0.1541
P047 1.103 4.577 92.3183 18.2932 129.9298
Ave (x) ¼ 29.6918 SD ¼ 6.6422
Table A7 e Normalized geometric mean count for ROI's in the femur.
Patient ID Administered activity (MBq) Area of ROI (mm2) GMC (cts) nGMC (cts/mm2/MBq) Error ðx xÞ2
P021 0.577 12.302 151.193 21.2926 14.3056
P028 0.740 12.595 127.950 13.7281 14.3056
Ave (x) ¼ 17.5104 SD ¼ 3.7823
Table A8 e Normalized geometric mean count for ROI's in the rib cage.
Patient ID Administered activity (MBq) Area of ROI (mm2) GMC (cts) nGMC (cts/mm2/MBq) Error ðx xÞ2
P036 0.463 3.271 118.246 78.1617 29.2122
P042 0.692 3.429 189.674 79.9460 51.6838
P043 0.681 3.271 175.954 79.0131 39.1399
P044 0.418 4.052 150.494 88.8320 258.4098
P046 1.006 3.649 138.931 37.8316 1219.7767
Ave (x) ¼ 72.7569 SD ¼ 17.8786
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Table A9 e Normalized geometric mean count for ROI's in the knee.
Patient ID Administered activity (MBq) Area of ROI (mm2) GMC (cts) nGMC (cts/mm2/MBq) Error ðx xÞ2
P001 0.929 20.808 199.324 10.3146 2.4130
P002 0.810 21.040 236.772 13.8880 4.0802
P003 0.704 21.186 223.728 14.9979 9.7963
P005 0.951 21.186 213.409 10.5932 1.6250
P007 0.814 20.747 200.261 11.8581 0.0001
P009 0.803 21.186 211.412 12.4285 0.3142
P010 0.814 21.040 193.810 11.3163 0.3043
P011 0.685 20.808 168.140 11.8050 0.0040
P012 0.910 21.186 176.560 9.1560 7.3550
P013 0.773 20.918 174.746 10.8029 1.1345
P015 0.777 21.198 179.294 10.8855 0.9653
P016 0.803 21.101 190.965 11.2717 0.3556
P017 0.673 21.186 172.829 12.1142 0.0606
P018 0.611 24.286 210.941 14.2272 5.5657
P019 0.503 20.991 155.464 14.7182 8.1238
P022 0.525 23.188 188.516 15.4737 13.0011
P025 0.618 24.030 210.107 14.1504 5.2092
P026 0.773 20.869 149.554 9.2672 6.7643
P027 0.688 20.991 174.943 12.1101 0.0586
P029 0.703 21.186 198.533 13.3299 2.1372
P030 0.788 21.186 215.270 12.8930 1.0505
P031 0.770 20.747 196.028 12.2772 0.1674
P032 0.951 20.991 180.676 9.0517 7.9314
P033 1.136 21.321 221.588 9.1495 7.3902
P036 0.463 21.186 144.407 14.7376 8.2347
P039 0.710 21.186 212.587 14.1249 5.0934
P040 0.784 21.198 194.132 11.6752 0.0372
P041 0.877 21.235 181.794 9.7629 4.4317
P042 0.692 21.260 207.418 14.1007 4.9848
P043 0.681 21.186 192.269 13.3303 2.1383
P046 1.006 21.260 173.973 8.1311 13.9647
P047 1.103 20.869 208.168 9.0468 7.9593
P048 1.173 21.260 215.814 8.6548 10.3250
Ave (x) ¼ 11.8680 SD ¼ 2.0815
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